The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma.
about
Second malignant neoplasms and cardiovascular disease following radiotherapy.The evolution of the diminishing role of extrapleural pneumonectomy in the surgical management of malignant pleural mesotheliomaApproach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentarySyntenic relationships between genomic profiles of fiber-induced murine and human malignant mesotheliomaCurrent issues in malignant pleural mesothelioma evaluation and managementEwing's Sarcoma as a Second Malignancy in Long-Term Survivors of Childhood Hematologic MalignanciesSubsequent malignancies among long-term survivors of Hodgkin lymphoma and non-Hodgkin lymphoma: a pooled analysis of German cancer registry data (1990-2012).Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma.Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005.Malignant pleural mesothelioma: a single-center experience in Turkey.MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma.Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtypeBreast ductal carcinoma and metastatic lymphoma to the contralateral breast in patient with cutaneous non-Hodgkin lymphoma.A novel radiation-induced p53 mutation is not implicated in radiation resistance via a dominant-negative effect.Second malignancies among elderly survivors of cancer.Second malignancies in patients with primary central nervous system lymphoma.Mesothelioma: a review.Risk Factors for Melanoma Among Survivors of Non-Hodgkin Lymphoma.Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor StudySecond malignant neoplasms following radiotherapy.Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration.Incidence, risk factors, and pathogenesis of second malignancies in patients with non-Hodgkin lymphoma.The rationale and role of radiation therapy in the treatment of patients with diffuse large B-cell lymphoma in the Rituximab era.PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.Radiation-induced cancer after radiotherapy for non-Hodgkin's lymphoma of the head and neck: a retrospective study.State of the evidence: the connection between breast cancer and the environment.Industrial-grade talc exposure and the risk of mesothelioma.The important role of radiation therapy in early-stage diffuse large B-cell lymphoma: time to review the evidence once again.Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors.An 8-Year-Old Child with Malignant Deciduoid Mesothelioma of the Abdomen: Report of a Case and Review of the Literature.Therapeutic radiation for lymphoma and risk of second primary malignant mesothelioma.Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: ReDevelopment of second primary malignancy in patients with non-Hodgkin lymphoma: a nationwide population-based study.Risk assessment of second primary cancer according to histological subtype of non-Hodgkin lymphoma.State of the evidence 2017: an update on the connection between breast cancer and the environmentDiffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions.Age-time risk patterns of solid cancers in 60 901 non-Hodgkin lymphoma survivors from Finland, Norway and Sweden.Risk of second malignant neoplasms after cyclophosphamide-based chemotherapy with or without radiotherapy for non-Hodgkin lymphoma.A Rare Differential Diagnosis of an Adrenal Mass: A Case Report.
P2860
Q26864522-8004A96C-E611-431F-9743-FD256E730452Q28067111-690D6DD7-2AB2-463A-9EA6-DE43C74CEF3BQ28088365-23F469BF-76B1-4441-B72F-5ACE359BF7E3Q28387443-63B341F1-929F-4B91-9BE9-07FC15D9E4BEQ28393560-79D05365-F3A1-4503-AA16-B22A07E34E58Q28598182-F3C67067-6BA5-4FF0-A224-C94912DCC610Q31155582-5774F89C-C779-4E3C-9A4E-B51A9C474D3BQ33397845-10F4AEE4-8985-414C-8B24-183B93E7A478Q33489828-67FE1A3A-D59C-4BE7-97BA-7F19EBC1BA91Q33686248-F0B1C803-76B5-4EA8-AA15-7AE86FBB4271Q34182679-8DB6BC38-0944-4B34-9086-E3C8DB6C5905Q34488720-F8EDE940-9AF5-4435-BA8B-C7A55ADCB4B0Q34976777-8FAD2612-A820-499F-9976-70807AB0AFCEQ35099489-6EAE657A-2C4F-417A-A665-B1BF23823E3CQ35599802-8195158A-662E-47B1-ACE5-941B2F5A08C7Q35788720-0FEFB247-C65B-4B9C-A18C-983552DDB90BQ35839385-03263C02-E45A-49AA-8F41-43547FA33B33Q36090959-DEBF9D0C-896F-4997-9526-4138E533BF25Q36528733-5BF3ADC2-BAD1-41BB-9112-62B9A75D7549Q36538754-0F75B9B7-B5E3-44EC-A4C9-308D927B0070Q36844307-5147A25B-FE97-45CE-90EC-47B81C3BEC5BQ36911493-32AECB48-122A-4F14-8787-F8D0FBA4E5BAQ36996280-62782F6A-BF08-4DDE-9A05-7673B7B77CDFQ37252398-9E5062DF-9652-47E7-AF7D-B05AB61EFB0EQ37278861-1C870931-6035-4C0B-ACE6-9267A7D61A81Q37408121-FA1530B9-D2EB-4B13-861E-046A3ECBA0B2Q37709395-BDCA546C-694C-4BAE-84F2-C2FB1669B3DAQ37934960-060CB450-505D-4CBE-877A-DB67015C4D81Q37973345-5CAB4B48-F856-4EFF-86F5-11EDA9653088Q38412665-2CAF03E8-E532-4A6E-8367-9C180C69309AQ38654138-6A2DCF16-ECB8-4A8D-89C7-6829161FFC91Q38679176-BD875407-AFD8-4B75-B7DC-9FD7EEEBE554Q40375360-4AAD5E8A-2AB5-41F4-9F7E-DFFC2E3703D8Q40942679-EE1508EF-410C-41FA-B82D-28C85CEBDAADQ41496252-36AA1A4F-E7AE-498C-9AE7-725375C19CE0Q41595188-39121A9C-CECD-4840-ADBB-A17E9A73386FQ43379691-DB8CF7BA-648B-4783-86A4-E4F5E099A3E2Q43467229-612BD3D6-5EB8-4012-A0F1-CA7126EDCF86Q44676921-70520B8F-BA98-4F12-8FF7-7BEE6BA135C5Q47154442-5CC6388A-07D2-4711-A36D-624E369EDCF1
P2860
The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
The risk of secondary malignan ...... tment of non-Hodgkin lymphoma.
@en
The risk of secondary malignan ...... tment of non-Hodgkin lymphoma.
@nl
type
label
The risk of secondary malignan ...... tment of non-Hodgkin lymphoma.
@en
The risk of secondary malignan ...... tment of non-Hodgkin lymphoma.
@nl
prefLabel
The risk of secondary malignan ...... tment of non-Hodgkin lymphoma.
@en
The risk of secondary malignan ...... tment of non-Hodgkin lymphoma.
@nl
P2093
P356
P1433
P1476
The risk of secondary malignan ...... atment of non-Hodgkin lymphoma
@en
P2093
Aniko Szabo
David K Gaffney
Dennis C Shrieve
Merideth M M Wendland
P2860
P304
P356
10.1002/CNCR.21971
P407
P577
2006-07-01T00:00:00Z